Latest News

FDA Accepts NDA for Anaphylm™, a Sublingual Epinephrine Film for Treatment of Severe Allergic Reactions
FDA Accepts NDA for Anaphylm™, a Sublingual Epinephrine Film for Treatment of Severe Allergic Reactions

June 17th 2025

The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026.

Study of Intranasal Epinephrine Powder (NS002) Published in Prestigious International Journal, Nasus Pharma Ltd Says / image credit ©MQ-Illustrations/stock.adobe.com
Phase 2 Dose-Finding Study of Intranasal Epinephrine Powder (NS002) Supports Development for Regulatory Submission

June 3rd 2025

Omalizumab Beats OIT in First Head-to-Head Multi-Food Allergy Trial: Daily Dose / image credit: ©New Africa/AdobeStock
Omalizumab Beats OIT in First Head-to-Head Multi-Food Allergy Trial: Daily Dose

March 28th 2025

Underutilization of Guideline-Recommended Epinephrine in Anaphylaxis Management: New Study / image credit ©Andrey Popov/AdobeStock
Underutilization of Guideline-Recommended Epinephrine in Anaphylaxis Management: New Study

March 26th 2025

Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose / image credit: ©New Africa/AdobeStock
Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose

March 24th 2025

Video Interviews
Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.